Back to discover

Protein / target

B-cell lymphoma 6 protein

Encoded byBCL6P41182Homo sapiensSwiss-Prot
Small-molecule tractable
Druggability
Structure with Ligand
2
Research papers

Protein at a glance

Biological role

Sequence-specific double-stranded DNA binding

Strongest disease association

Lymphoid neoplasm

Via encoding gene BCL6 · Genetic evidence · score 0.28

Research activity

Emerging research

2 papers · latest 2024

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Transcriptional repressor mainly required for germinal center (GC) formation and antibody affinity maturation which has different mechanisms of action specific to the lineage and biological functions.

View complete UniProt function annotation

Transcriptional repressor mainly required for germinal center (GC) formation and antibody affinity maturation which has different mechanisms of action specific to the lineage and biological functions. Forms complexes with different corepressors and histone deacetylases to repress the transcriptional expression of different subsets of target genes. Represses its target genes by binding directly to the DNA sequence 5'-TTCCTAGAA-3' (BCL6-binding site) or indirectly by repressing the transcriptional activity of transcription factors. In GC B-cells, represses genes that function in differentiation, inflammation, apoptosis and cell cycle control, also autoregulates its transcriptional expression and up-regulates, indirectly, the expression of some genes important for GC reactions, such as AICDA, through the repression of microRNAs expression, like miR155. An important function is to allow GC B-cells to proliferate very rapidly in response to T-cell dependent antigens and tolerate the physiological DNA breaks required for immunoglobulin class switch recombination and somatic hypermutation without inducing a p53/TP53-dependent apoptotic response. In follicular helper CD4(+) T-cells (T(FH) cells), promotes the expression of T(FH)-related genes but inhibits the differentiation of T(H)1, T(H)2 and T(H)17 cells. Also required for the establishment and maintenance of immunological memory for both T- and B-cells. Suppresses macrophage proliferation through competition with STAT5 for STAT-binding motifs binding on certain target genes, such as CCL2 and CCND2. In response to genotoxic stress, controls cell cycle arrest in GC B-cells in both p53/TP53-dependedent and -independent manners. Besides, also controls neurogenesis through the alteration of the composition of NOTCH-dependent transcriptional complexes at selective NOTCH targets, such as HES5, including the recruitment of the deacetylase SIRT1 and resulting in an epigenetic silencing leading to neuronal differentiation

Subcellular location

Nucleus
Domains and Gene Ontology detail (34)

Domains & features

BTB

Gene Ontology

  • Cnucleoplasm
  • Cnucleus
  • Cparaspeckles
  • Fchromatin binding
  • Fchromatin DNA binding
  • FDNA-binding transcription factor activity
  • FDNA-binding transcription factor binding
  • FDNA-binding transcription repressor activity, RNA polymerase II-specific
  • Fidentical protein binding
  • Fintronic transcription regulatory region sequence-specific DNA binding
  • FRNA polymerase II cis-regulatory region sequence-specific DNA binding
  • Fsequence-specific DNA binding

706 aa · 79 kDa · 2 isoforms

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Cell-cycle regulationUniProt · GOCell proliferation & survivalGOImmune signallingUniProt · GOTranscriptional regulationUniProt · GOApoptosis & cell deathGO
View supporting evidence

Cell-cycle regulation

  • ·Transcriptional repressor mainly required for germinal center (GC) formation and antibod…
  • ·negative regulation of mitotic cell cycle DNA replication

Cell proliferation & survival

  • ·regulation of cell population proliferation

Immune signalling

  • ·Transcriptional repressor mainly required for germinal center (GC) formation and antibod…
  • ·inflammatory response
  • ·negative regulation of B cell apoptotic process
  • ·positive regulation of regulatory T cell differentiation

Transcriptional regulation

  • ·Transcriptional repressor mainly required for germinal center (GC) formation and antibod…
  • ·DNA-binding transcription factor activity
  • ·DNA-binding transcription factor binding
  • ·DNA-binding transcription repressor activity, RNA polymerase II-specific

Apoptosis & cell death

  • ·negative regulation of B cell apoptotic process
  • ·positive regulation of apoptotic process

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene BCL6

Gene-level evidence surfaced through the gene BCL6that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Lymphoma
0.67Moderately supported

Somatic mutation evidence dominant · Open Targets 0.40

Lymphoid neoplasm
0.57Moderately supported

Somatic mutation evidence dominant · Open Targets 0.41

Lymphoma, Large B-Cell, Diffuse
0.52Moderately supported

Somatic mutation evidence dominant · Open Targets 0.52

Lung carcinoma
0.46Limited support

Somatic mutation evidence dominant · Open Targets 0.39

Multiple Myeloma
0.42Limited support

Somatic mutation evidence dominant · Open Targets 0.38

View evidence synthesis (5)
LymphomaModerately supported
0.67
agreement 0.570.77
Somatic mutation36%Pathway25%Genetic24%Literature14%

Open Targets aggregate 0.40 · 4 independent evidence families

Lymphoid neoplasmModerately supported
0.57
agreement 0.460.68
Somatic mutation57%Genetic41%Literature2%

Open Targets aggregate 0.41 · 3 independent evidence families

Lymphoma, Large B-Cell, DiffuseModerately supported
0.52
agreement 0.360.68
Somatic mutation75%Literature25%

Open Targets aggregate 0.52 · 2 independent evidence families

Lung carcinomaLimited support
0.46
agreement 0.320.60
Somatic mutation78%Literature19%RNA expression3%

Open Targets aggregate 0.39 · 3 independent evidence families

Multiple MyelomaLimited support
0.42
agreement 0.260.58
Somatic mutation92%Literature8%

Open Targets aggregate 0.38 · 2 independent evidence families

This ranking differs from Open Targets' own: re-weighting moves genetically-evidenced diseases above more heavily co-mentioned ones. The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Lymphoma, Large B-Cell, Diffuse0.52
Neurodegenerative Diseases0.48
Lymphoid neoplasm0.41
Lymphoma0.40
Lung carcinoma0.39
Multiple Myeloma0.38
Colorectal adenocarcinoma0.37
Skin squamous cell carcinoma0.37
Hemangioblastoma0.37

Tractability

Small moleculesEmerging

Feasibility evidence (structure with ligand and high-quality ligand) — no clinical-stage drug of this modality recorded.

Protein degradersEmerging

Feasibility evidence (literature and uniprot ubiquitination) — no clinical-stage drug of this modality recorded.

View underlying tractability evidence (7)
SM · Structure with LigandSM · High-Quality LigandSM · Med-Quality PocketPR · LiteraturePR · UniProt UbiquitinationPR · Database UbiquitinationPR · Small Molecule Binder

Raw Open Targets tractability assessment buckets, by modality.

Research activity

2 papers · to 2024

Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.

Most cited

Vinuesa CG · Annual review of immunology · 2016

Liongue C · International journal of molecular sciences · 2024

Recent

B Cell Lymphoma 6 (BCL6): A Conserved Regulator of Immunity and Beyond.

Liongue C · International journal of molecular sciences · 2024

Follicular Helper T Cells.

Vinuesa CG · Annual review of immunology · 2016

Europe PMC papers linked directly to this protein.